Interferon beta 1b following natalizumab discontinuation.
One year, randomized, prospective, pilot trial (Gobbi C, Meier DS, Cotton F, Sintzel MB, et al. BMC Neurol. 2013;13:101). Support of the team at the Civico Hospital in Lugano, Switzerland, to design and conceptualize the study and revising the manuscript for intellectual content. Project supported by Bayer Switzerland.